Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care
Glioblastoma (GB) is a primary brain tumor that is lethal and challenging to treat. The 3-year overall survival (OS) of patients with this diagnosis has stayed the same since 2005. The patient is a 75-year-old woman who presented with progressive aphasia and was diagnosed with GB (WHO grade 4, IDH1/...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1501466/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542395425619968 |
|---|---|
| author | Midhad Mrvoljak Midhad Mrvoljak Shubhendu Mishra Liam Chen Liam Chen Elizabeth Neil Elizabeth Neil Eric Ehler Stephanie Terezakis Stephanie Terezakis Lindsey Sloan Lindsey Sloan |
| author_facet | Midhad Mrvoljak Midhad Mrvoljak Shubhendu Mishra Liam Chen Liam Chen Elizabeth Neil Elizabeth Neil Eric Ehler Stephanie Terezakis Stephanie Terezakis Lindsey Sloan Lindsey Sloan |
| author_sort | Midhad Mrvoljak |
| collection | DOAJ |
| description | Glioblastoma (GB) is a primary brain tumor that is lethal and challenging to treat. The 3-year overall survival (OS) of patients with this diagnosis has stayed the same since 2005. The patient is a 75-year-old woman who presented with progressive aphasia and was diagnosed with GB (WHO grade 4, IDH1/IDH2 wild type, ATRX intact, p53 and PTEN mutant, BRAF non-mutated, O6-methylguanine-DNA methyltransferase promoter methylated) and who underwent surgical resection, hypofractionated radiotherapy (HFRT) using intensity-modulated radiotherapy (IMRT) (4,005 cGy in 15 fractions) alone, and adjuvant temozolomide (TMZ). She was progression-free for approximately 20 months. Although planned, concurrent TMZ was not used during the complete first course of HFRT due to the patient’s performance status. After recurrence, another HFRT (35 Gy in 10 fractions) was employed. She was progression-free on imaging for 8 months until a recent follow-up scan showed potential progression versus radiation-related change. At the time of this case report, her care is still ongoing. This represents a rare case of a long-term survivor of GB who has received two courses of HFRT, a treatment option that is usually used in those with predicted shorter survival times. |
| format | Article |
| id | doaj-art-ab9bfab413cf40279d37a88b942e8f4d |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ab9bfab413cf40279d37a88b942e8f4d2025-02-04T05:27:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15014661501466Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her careMidhad Mrvoljak0Midhad Mrvoljak1Shubhendu Mishra2Liam Chen3Liam Chen4Elizabeth Neil5Elizabeth Neil6Eric Ehler7Stephanie Terezakis8Stephanie Terezakis9Lindsey Sloan10Lindsey Sloan11College of Osteopathic Medicine, Des Moines University, Des Moines, IA, United StatesDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United StatesDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United StatesMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United StatesDepartment of Pathology, University of Minnesota Medical School, Minneapolis, MN, United StatesMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United StatesDepartment of Neurology, University of Minnesota Medical School, Minneapolis, MN, United StatesDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United StatesDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United StatesMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United StatesDepartment of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, United StatesMasonic Cancer Center, University of Minnesota, Minneapolis, MN, United StatesGlioblastoma (GB) is a primary brain tumor that is lethal and challenging to treat. The 3-year overall survival (OS) of patients with this diagnosis has stayed the same since 2005. The patient is a 75-year-old woman who presented with progressive aphasia and was diagnosed with GB (WHO grade 4, IDH1/IDH2 wild type, ATRX intact, p53 and PTEN mutant, BRAF non-mutated, O6-methylguanine-DNA methyltransferase promoter methylated) and who underwent surgical resection, hypofractionated radiotherapy (HFRT) using intensity-modulated radiotherapy (IMRT) (4,005 cGy in 15 fractions) alone, and adjuvant temozolomide (TMZ). She was progression-free for approximately 20 months. Although planned, concurrent TMZ was not used during the complete first course of HFRT due to the patient’s performance status. After recurrence, another HFRT (35 Gy in 10 fractions) was employed. She was progression-free on imaging for 8 months until a recent follow-up scan showed potential progression versus radiation-related change. At the time of this case report, her care is still ongoing. This represents a rare case of a long-term survivor of GB who has received two courses of HFRT, a treatment option that is usually used in those with predicted shorter survival times.https://www.frontiersin.org/articles/10.3389/fonc.2025.1501466/fullglioblastomalong-term survivorhypofractionated radiotherapycase reportreirradiation |
| spellingShingle | Midhad Mrvoljak Midhad Mrvoljak Shubhendu Mishra Liam Chen Liam Chen Elizabeth Neil Elizabeth Neil Eric Ehler Stephanie Terezakis Stephanie Terezakis Lindsey Sloan Lindsey Sloan Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care Frontiers in Oncology glioblastoma long-term survivor hypofractionated radiotherapy case report reirradiation |
| title | Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| title_full | Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| title_fullStr | Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| title_full_unstemmed | Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| title_short | Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| title_sort | case report a rare case of a long term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of her care |
| topic | glioblastoma long-term survivor hypofractionated radiotherapy case report reirradiation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1501466/full |
| work_keys_str_mv | AT midhadmrvoljak casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT midhadmrvoljak casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT shubhendumishra casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT liamchen casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT liamchen casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT elizabethneil casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT elizabethneil casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT ericehler casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT stephanieterezakis casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT stephanieterezakis casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT lindseysloan casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare AT lindseysloan casereportararecaseofalongtermsurvivorofglioblastomawhounderwenttwocoursesofhypofractionatedradiotherapyaspartofhercare |